Menu
MapConnectionsTopicsBulgariaThe Night (K-TRIO)Marie Skłodowska-CurieFor studentsFor teachersMethodologySurprise me
H2020Staff exchange2018–2023

CISTEM · Heart On chip based on induced pluripotent Stem cell Technology for personalized Medicine

Horizon 2020 — Marie Skłodowska-Curie Actions

Duration
2018-01-01 → 2023-06-30
EU contribution
€364,500
Participants
8
Scheme
MSCA-RISE

Lines connect the coordinator with its partners.

Results in brief

Heart On chip based on induced pluripotent Stem cell Technology for personalized Medicine

Duchenne muscular dystrophy (DMD) is a serious genetic disorder, occurring in 1/3 500- 5000 children and develops due to mutation in dystrophin gene. Cardiomyopathy in DMD develops in the second decade of life in the significant proportion of patients (more than 60% at age of more than 18 years) together with the respiratory failure and both ultimately lead to death in second or third decade of life. Understanding the mechanisms of cardiomyopathy can provide better chance for patients, improving their conditions of life and prolonging its extent. However, the available animal models only partially reflect the severity of human diseases. In parallel, due to the variability in disease mechanisms, medications and dosages may vary among patients, making it difficult the provision of universally efficacious treatment, creating a tremendous burden on the healthcare system. Microfluidic technology-based “Organs-on-a-chip” like “Heart-on-a-chip” that mimic tailored micro-environment architecture inspired by organ-level functions in vivo represents a powerful tool for investigating DMD disease mechanisms and testing new drug and treatment. Its conjunction with hiPSCs (Human-induced pluripotent stem cells) might offer an excellent opportunity to engineer heart-on-a-chip in a patient-matched manner and overcome the variability in DMD disease mechanisms that can occur from one patient to another. CISTEM project aims to merge recent progress in stem cell biology and advanced microfluidic and MEMS technologies in order to develop a novel “heart-on-chips” platform based on iPSCs-derived cardiomyocytes and to propose a new model of DMD-cardiomyopathy. To achieve this objective, CISTEM has defined two main steps: • Engineering Heart–on-a-Chip from Cardiomyocytes-derived hiPSCs using microfluidic and microsystem technologies • Use of the developed platform to model and investigate the cardiomyopathy coming from the Duchenne muscular dystrophy. In addition, CISTEM project aims also to implement a high quality staff exchange programme in order to : • Connect high-quality research infrastructures using them as training facilities for developing and completing the skills of the CISTEM’participants • Contribute to bridging the gap between industry and high education institutions by implementing a structured secondment-based exchange programme

Data: CORDIS, © European Union

Project objective

Many rare diseases cause chronic health problems or are even life-threatening. The impact on the quality of life of affected patients, of whom many are children, is significant. To date, a limited but increasing number of so-called orphan drugs (drugs for rare diseases) are reaching patients. However, the majority of rare diseases are still without any effective treatment. The development of novel human systems for drug discovery therefore represents a major public health priority. Microfluidic technology-based “Organs-on-a-chip” represents a powerful tool for investigating rare disease mechanisms and testing new drug and treatment due to their ability to mimic tailored micro-environment architecture inspired by organ-level functions in vivo. However, due to the variability in rare disease mechanisms from one patient to another, organ on chip technology needs to be more precise and to convey towards personalized medicine. The human-induced pluripotent stem cells (iPSCs) have a strong potential in engineering organ-on-a-chip since they are derived in a patient-matched manner which makes them a superb source to construct human models for personalized drug screening as well as for understanding patient-specific fundamentals of diseases. To provide novel miniaturized platform for investigation of rare diseases able to address the burning issues in precision medicine today, CISTEM will bring together and synergistically several highly promising research directions which are too often investigated separately at the academic level but also at the industrial level. Based on 4 work packages, the CISTEM RISE project will be implemented by exploiting the complementary expertise of its partners and creating synergies between them through the targeted secondments of staff.

Original text from CORDIS.

Participants

  • BIOSENSE INSTITUTE - RESEARCH AND DEVELOPMENT INSTITUTE FOR INFORMATION TECHNOLOGIES IN BIOSYSTEMS · Novi SadCoordinatorSerbia
  • BEONCHIP SL · ZaragozaSpain
  • CHERRY BIOTECH · MONTREUILFrance
  • ELVESYS · PARISFrance
  • RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY · New BrunswickUnited States
  • UNIVERSIDAD DE BUENOS AIRES · Buenos AiresArgentina
  • UNIVERSIDAD DE ZARAGOZA · ZaragozaSpain
  • UNIWERSYTET JAGIELLONSKI · KrakowPoland

Links

Data: CORDIS, © European Union